CTMX News and Press, CytomX Therapeutics Inc. From 11/04/25

- CX-801 (PROBODY ® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma - - Data supportive of CX-801’s mechanism of action and the ongoing Phase 1 combination study with KEYTRUDA ® ...

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial results on Thursday, November 6, 2025, after the close of U.S. m...

2025-10-21 06:15:05 ET Barclays analyst issues OVERWEIGHT recommendation for CTMX on October 21, 2025 09:19AM ET. The previous analyst recommendation was Overweight. CTMX was trading at $3.74 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice President, Chief Business Officer. In this role, Ms. Lester...

2025-10-16 11:17:03 ET More on the markets: Chair Powell's New Revelations On Monetary Policy Small Caps Don't Make All-Time Highs On The Cusp Of A Downturn 5 Trend Indicators For Deciding If The Bull Market Is Breaking Down U.S. stocks add to gains as more c...

2025-10-13 23:45:00 ET ... Read the full article on Seeking Alpha For further details see: CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible

2025-10-12 05:00:27 ET Renewed Tariff Fears Spotlight Top Performers Since April Tariff fears have returned to markets just as stocks ended a week that coincidentally notched six months since the April "Tariff Tantrum" selloff. The S&P 500 tumbled 2.7% Friday, its worst day since th...

2025-10-06 11:20:56 ET Introduction My 2018 rating on CytomX Therapeutics ( CTMX ) was buy with hopes that its "Probody therapeutic technology" would bear fruit amid a “pretty high” valuation. After a few years of clinical trial failures, CTMX has since cratered 87...

2025-09-25 15:30:29 ET DENVER, Colo., Sep 25, 2025 ( 247marketnews.com )- Kraig Biocraft Laboratories (OTCQB:KBLB) is in the spotlight after announcing the completion of its first simultaneous dual‑facility production cycle, a major operational breakthrough for its recombinan...

2025-09-10 16:26:32 ET CytomX Therapeutics, Inc. (CTMX) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 1:05 PM EDT... Read the full article on Seeking Alpha For further details see: CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd ...